Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES TTS 2 versus CATAPRES TTS 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES TTS 2 versus CATAPRES TTS 3.
CATAPRES-TTS-2 vs CATAPRES-TTS-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clonidine is a centrally acting alpha-2 adrenergic agonist that stimulates alpha-2 adrenergic receptors in the brainstem, activating inhibitory neurons and reducing sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, heart rate, and blood pressure.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Transdermal patch delivering 0.2 mg/day clonidine applied every 7 days to hairless area of upper arm or chest.
Transdermal patch: 0.3 mg/day applied once every 7 days; initial dose 0.1 mg/day, titrate weekly by 0.1 mg/day increments to desired response.
None Documented
None Documented
Terminal elimination half-life: 12–16 hours (up to 48 hours following transdermal administration due to continued absorption from the skin depot).
Terminal elimination half-life is 12-16 hours after oral administration; with transdermal delivery, the effective half-life is prolonged to 20-40 hours due to continued absorption from the skin depot. In renal impairment, half-life may extend to 40 hours or longer.
Renal: ~65% as unchanged drug; biliary/fecal: ~20% as metabolites; about 15% eliminated as metabolites in urine.
Approximately 40-60% of the absorbed dose is excreted unchanged in urine. About 20-30% is eliminated as metabolites via bile and feces. Renal clearance accounts for 50-60% of total clearance.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist